An interventional study of H.A.L.T. MAX spectacles in Myopia and High Myopia, sponsored by Shanghai Eye Disease Prevention and Treatment Center. Withdrawn at 1 site in China. Open to participants aged 7 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Shanghai Eye Disease Prevention and Treatment Center · Not applicable, Interventional, and Prevention
Major amendment for protocol
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center — 21 open to participants now, 22 under way, none of them phase 3. Myopia · Shanghai Eye Disease Prevention and Treatment Center.
Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, this one is the 36th largest by enrollment of the 36 interventional ones that give a count, is one of 10 that started in 2026, is one of 32 with no phase, and was the 29th registered.
1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →21 of the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center are open now, in 1 country. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 18–55
By country, each count listing its studies:
Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.
This study: 7 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 141 across the 36 interventional studies, 9,500 across the 6 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Eye Disease Prevention and Treatment Center is the lead sponsor of 67 studies on the registry; 31 are open to participants now.
9 of the studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770661Shanghai Eye Disease Prevention and Treatment CenterChina Children Eye Study | 2026-12-31 |
| NCT07746804Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Prevention Trial for Children With Insufficient Hyperopic Reserve | 2027-06 |
| NCT07746752Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Prevention Trial for Children With Adequate Hyperopic Reserve | 2027-06 |
| NCT07746778Shanghai Eye Disease Prevention and Treatment CenterSchool-based Myopia Control Trial for Children With Premyopia or Myopia | 2027-06 |
| NCT07176949Shanghai Eye Disease Prevention and Treatment CenterEarly-Onset Myopia Intervention Project | 2027-06-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 42 studies in Myopia by Shanghai Eye Disease Prevention and Treatment Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Children aged 7-14 years with high myopia were randomly assigned to a control group or an intervention group at a 1:1 ratio. The intervention group wore H.A.L.T. MAX lenses for at least 10 hours per day for 2 years, and the control group wore ordinary single-vision (SV) spectacles for at least 10 hours per day. At the 1-year follow-up examination (6-month visit), control subjects whose equivalent spherical diopter change (SER) was ≥0.75 D were switched to H.A.L.T. MAX lenses until the end of year 2. After entering year 2, all remaining control (SV) subjects will be replaced with H.A.L.T. MAX defofocus frames for at least 10 hours per day until the end of year 2. And continue to wear it for at least 10 hours per day. To evaluate the efficacy, safety and compliance of H.A.L.T. MAX lenses in delaying myopia progression in children with high myopia, and to provide a scientific basis for the formulation and practice of public health programs for delaying myopia progression and the risk of blindness and visual impairment caused by high myopia.
In a 2-year randomized controlled study, the intervention group wear H.A.L.T. MAX spectacle lenses for more than 10 hours a day for 2 years. During the first year, the control group wore conventional single-vision (SV) spectacles for at least 10 hours per day. At the 6-month follow-up visit, if the spherical equivalent refraction (SER) change in the control group (SV) participants was ≥0.75 D, they were switched to H.A.L.T. MAX spectacle lenses until the end of the second year. In the second year, all remaining control group (SV) participants were transitioned to H.A.L.T. MAX defocus spectacle lenses and continued wearing them until the study concluded. To evaluate the efficacy, safety and compliance of H.A.L.T. MAX lenses for delaying myopia in children with high myopia, and to provide a scientific basis for the development of prevention strategies for children with high myopia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
the intervention group wore H.A.L.T. MAX for at least 10 hours a day for 2 years.
Device: H.A.L.T. MAX spectacles
The control group will wear single vision lenses (SV) for at least 10 hours a day. In the first year (at 6-month follow-up), study participants in the control group with a spherical equivalent diopter change (SER) of ≥0.75 D will be switched to H.A.L.T. MAX lenses until the end of year 2. After entering year 2, all remaining control (SV) study participants will be replaced with H.A.L.T. MAX spectacles for at least 10 hours per day until the end of year 2.
The Essilor® Stellest® 2.0 lens features a 2 times larger signal area, significantly enhancing the effect of slowing down myopia progression
the proportion of change in SER of ≤ -0.75 (D)
the proportion of change in SER of ≤ -0.75 (D) at the end of 1-year in both groups
Time frame: at the end of 1-year
The proportion of change in AL of ≥ 0.34 mm
The proportion of change in AL of ≥ 0.34 mm at the end of 1-year in both groups
Time frame: at the end of 1-year
Adaptation outcome
visual quality, assessed by specify questionnaire.
Time frame: at the end of 1-year
Adverse events incidence
Number of participants with adverse events (e.g., headache, dizziness) attributed to lens wear.
Time frame: 1 year
Exploratory outcomes1
Changes in SER and AL in the SVL switch over group in the second year.
Time frame: at the end of 2-year
Exploratory outcomes2
Changes in choroidal thickness from baseline in the intervention and control group by OCT.
Time frame: at the end of 2-year
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2026 to primary completion in Oct 2026, 0 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Sep 2025 → Oct 2026, primary completion Mar 2028 → Oct 2026 and completion Dec 2028 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Major amendment for protocol
Major amendment for protocol
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Eye Disease Prevention and Treatment Center